Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

Approximately 25-30% of lung cancer patients lack mutations targeted by current therapies, necessitating novel approaches. New targets, including MTAP deletions, SMARC4, and p53 mutations, show ...

Investigators at Cold Spring Harbor Laboratory say they've identified a biomarker that can quickly highlight a potentially deadly mutation in p53, a natural tumor suppressor. They found that the ...

A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas. When ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

PMV Pharmaceuticals, Inc. reported a corporate update and financial results for the first quarter of 2025, focusing on the ongoing Phase 2 PYNNACLE clinical trial evaluating rezatapopt, a treatment ...